Featured Publications
Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease
Leeds IL, Sklow B, Gorgun E, Liska D, Lightner AL, Hull TL, Steele SR, Holubar SD. Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease. Journal Of Gastrointestinal Surgery 2022, 26: 1275-1285. PMID: 35277799, DOI: 10.1007/s11605-022-05287-z.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease surgeryLow-dose aspirinQuality-adjusted life yearsThromboembolism prophylaxisDisease surgeryUnfavorable incremental cost-effectiveness ratiosLife yearsExtended venous thromboembolism prophylaxisPost-discharge event ratePocket costsIncremental cost-effectiveness ratioVenous thromboembolism prophylaxisEfficacy of aspirinInflammatory bowel diseaseMedian hospital costsMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioProbabilistic sensitivity analysesDecision analysis modelEnoxaparin regimenThromboembolism ratesVenous thromboembolismBowel diseaseColorectal surgeryCase patients
2024
Long-term Outcomes Following Colectomy and Liver Transplantation for Inflammatory Bowel Disease with Primary Sclerosing Cholangitis.
Matar A, Falconer E, LaBella M, Kapadia M, Justiniano C, Olortegui K, Steinhagen R, Schultz K, Pratap A, Leeds I, Weaver L, Gaertner W, Finger E, Thompson M, Fair L, Fichera A, Lovasik B, Chapman W, McGeoch C, Camacho M, Kazimi M, Kim S, Shaffer V, Srinivasan J. Long-term Outcomes Following Colectomy and Liver Transplantation for Inflammatory Bowel Disease with Primary Sclerosing Cholangitis. Annals Of Surgery 2024 PMID: 39258375, DOI: 10.1097/sla.0000000000006533.Peer-Reviewed Original ResearchTotal abdominal colectomyLong-term outcomesIleal pouch anal anastomosisMedically refractory diseaseLiver transplantationPSC-IBDRecurrent PSCRefractory diseaseBiliary complicationsMedian timeLong-term outcomes of patientsBowel diseasePost-LT survivalOutcomes of patientsPrimary sclerosing cholangitisFraction of patientsPSC-IBD patientsLong-term survivalInflammatory bowel diseasePost-LTSclerosing cholangitisPediatric patientsAbdominal colectomyEnd ileostomyLT survival
2023
Perioperative Immunosuppression in Inflammatory Bowel Disease
Leeds I, Lightner A, Kurowski J. Perioperative Immunosuppression in Inflammatory Bowel Disease. 2023, 613-617. DOI: 10.1007/978-3-031-14744-9_43.ChaptersInflammatory bowel diseaseBowel diseasePotential postoperative morbidityChronic steroid useEndoscopic remissionPostoperative morbidityPerioperative effectsPerioperative periodPharmacologic therapyPostoperative outcomesPerioperative immunosuppressionUlcerative colitisCrohn's diseaseImmunosuppressive agentsOpportunistic infectionsSteroid useImmunosuppressive effectsImmunosuppressive propertiesMonoclonal antibodiesDiseaseImmunosuppressionHigh rateRiskColitisCorticosteroids
2019
Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease
Truta B, Leeds IL, Canner JK, Efron JE, Fang SH, Althumari A, Safar B. Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019, 26: 1110-1117. PMID: 31670762, DOI: 10.1093/ibd/izz250.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseIFX groupDisease activityIFX discontinuationSteroid prescriptionEarly discontinuationPregnancy outcomesPreterm babiesBowel diseaseRisk babiesPregnant womenTruven Health Analytics MarketScan databaseContinuation of infliximabMore preterm babiesAcute respiratory infectionsPoor pregnancy outcomesIntrauterine growth retardationRisk of diseaseDisease flareIBD mothersIBD patientsFetal exposureHospital admissionRespiratory infectionsMarketScan database